CAMP cGMP PDE NO
K |
|||
| (4 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) | |||
| Zeile 1: | Zeile 1: | ||
| + | {{up|PHA conventional pharmacology}} | ||
'''Nitric oxide''' | '''Nitric oxide''' | ||
| Zeile 7: | Zeile 8: | ||
{{tp|p=32579020|t=2020. Treatment of COVID-19 by Inhaled NO to Reduce Shunt?|pdf=|usr=010}} | {{tp|p=32579020|t=2020. Treatment of COVID-19 by Inhaled NO to Reduce Shunt?|pdf=|usr=010}} | ||
{{tp|p=32590117|t=2020. Nitric oxide dosed in short bursts at high concentrations may protect against Covid 19.|pdf=|usr=010}} | {{tp|p=32590117|t=2020. Nitric oxide dosed in short bursts at high concentrations may protect against Covid 19.|pdf=|usr=010}} | ||
| + | {{tp|p=32539647|t=2020. Inhaled nitric oxide treatment in spontaneously breathing COVID-19 patients.|pdf=|usr=011}} | ||
| + | |||
| + | |||
'''PDE4 Inhibitors''' | '''PDE4 Inhibitors''' | ||
{{tp|p=32497535|t=2020. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.|pdf=|usr=009}} | {{tp|p=32497535|t=2020. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.|pdf=|usr=009}} | ||
| + | {{tp|p=32574572|t=2020. Letter to the editor: Immunomodulation by phsphodiesterase-4 inhibitor in COVID-19 patients.|pdf=|usr=010}} | ||
| + | {{tp|p=32558435|t=2020. Rationale for Evaluating PDE4 Inhibition for Mitigating against Severe Inflammation in COVID-19 Pneumonia and Beyond.|pdf=|usr=011}} | ||
| + | |||
'''PDE5 Inhibitors''' | '''PDE5 Inhibitors''' | ||
{{tp|p=32272196|t=2020. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology |pdf=|usr=}} | {{tp|p=32272196|t=2020. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology |pdf=|usr=}} | ||
{{tp|p=32226695|t=ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}} | {{tp|p=32226695|t=ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}} | ||
| + | {{tp|p=32573126|t=2020. Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?|pdf=|usr=011}} | ||
Aktuelle Version vom 18. Januar 2021, 20:25 Uhr
| PHA conventional pharmacology |
Nitric oxide
32526061 2020. Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection.
32387333 ä. Could nasal nitric oxide help to mitigate the severity of COVID-19?
32436029 2020. Nitric oxide inhalation as an interventional rescue therapy for COVID-19-induced acute respiratory distress syndrome.
32454510 2020. Potential Immunoregulatory and Antiviral/SARS-CoV-2 Activities of Nitric Oxide.
32579020 2020. Treatment of COVID-19 by Inhaled NO to Reduce Shunt?
32590117 2020. Nitric oxide dosed in short bursts at high concentrations may protect against Covid 19.
32539647 2020. Inhaled nitric oxide treatment in spontaneously breathing COVID-19 patients.
PDE4 Inhibitors
32497535 2020. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.
32574572 2020. Letter to the editor: Immunomodulation by phsphodiesterase-4 inhibitor in COVID-19 patients.
32558435 2020. Rationale for Evaluating PDE4 Inhibition for Mitigating against Severe Inflammation in COVID-19 Pneumonia and Beyond.
PDE5 Inhibitors
32272196 2020. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology
32226695 ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)
32573126 2020. Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?
